there seems to be some heavy resistance around these level with a lot of potential upside.

GSK China consumer healthcare unit linked to DOJ probe in 2012

(Reuters) - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

GSK confirmed it had conducted an investigation into procurement practices in consumer healthcare in China, but said it did not find any "unethical conduct". It said the inquiry was unrelated to a Chinese criminal investigation into corruption in its pharmaceuticals division that was made public last year.

Sept 10: Deutsche; Hold - TP: 1500p - Reiterates.

Seems to be Deutsche's new baby.

Well I hope they have more success here than with TW.!!

They seem to have gone cold on TW....

Sept 11;
Berenberg; Hold - TP: 1575p
JP Morgan: Neutral - No TP

Their last TP was £17 on 17 June, so I guess that still stands.

Yesterday's JPMorgan TP was 1446p.

Midknight - their last TP on 17 Jun was £17 - GSK Broker notes

Skinny, if interested you can get a daily email update re brokers' forecasts for all stocks
here. I never give my name or anything personal. Just email address.

Thanks Midknight - I've had a look but can't see a JPM TP of 1446p?

Skinny, I got the 1446 from here.

Ok thanks - obviously conflicting data!

From the Digital page, it seems there may have been a JPM forecast
after 17 June as well, as the TP is given as unchanged from the previous 1446p TP
given there.

On the LSE site, it shows your figure yesterday, but shows no other JPM update going back til 18th July - so if there was a TP price change, it must have been between 17th June and 17th July.

Anyway a tad frustrating.

Sept 15: Deutsche: Hold - Reduces TP from 1500p to 1450p.

Ebola news

Skin cancer drug deal

GSK China Investigation Outcome

GlaxoSmithKline plc (GSK) today announced that the Changsha Intermediate People's Court in Hunan Province, China ruled that GSK China Investment Co. Ltd (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China's Ministry of Public Security in June 2013.

As a result of the Court's verdict, GSKCI will pay a fine of £297 million (3 billion RMB at a currency exchange rate of 10.0980) to the Chinese government. This will be funded through existing cash resources. Associated costs and charges related to restructuring will be included in GSK's third quarter update.

The illegal activities of GSKCI are a clear breach of GSK's governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com).

GSK has co-operated fully with the authorities and has taken steps to comprehensively rectify the issues identified at the operations of GSKCI. This includes fundamentally changing the incentive program for its salesforces (decoupling sales targets from compensation); significantly reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments.

Ex-head to be deported not jailed

Sept 22: Goldman Sachs: Buy - TP: 1670p

Sept 20: Questor/Telegraph